Answers are grounded in this paper and cite their sources.
This real-world study demonstrates that lanadelumab long-term prophylaxis is effective in improving AFR in patients with type I/II HAE on every 2-week dosing and dose interval increases. Effectiveness with lanadelumab is rapid and was observed starting from the first month of starting therapy.
No takes yet. Share an insight, caveat, or question.
Magerl et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: